Neurostimulation Devices Market (2nd Edition), 2018-2030

The National Academy of Medicine indicates that as many as 100 million people in the US suffer from some form of pain, which has been shown to be associated with a socioeconomic burden of around USD 600 billion per year, in treatment costs and lost productivity. Further, it has been estimated that nearly 1 million people in America suffer from Parkinson’s disease, with approximately 60,000 new patients being diagnosed every year. Over the past few decades, the prevalence of such chronic disorders has grown at an alarming rate. In fact, a recent World Health Organization’s Global Burden of Disease study recognized these chronic conditions as one of the leading causes of deteriorating public health in the world. Such clinical conditions have often been shown to result in serious physical, cognitive and psychosocial consequences in patients. This indicates an urgent need for novel and effective treatment methods as the drawbacks of existing treatment options (such as high risk of addiction/abuse associated with long-term use of oral opioids, and complications due to complex surgical procedures) are substantial.
Extensive research in the field of neurostimulation has demonstrated the potential of this technique in providing therapeutic relief to a number of patients, who have developed resistance to conventional medication. Since the introduction of the first neurostimulation therapy in 1960s, their numerous observed benefits, such as reversible and minimally invasive nature of the procedures (to administer such treatments), targeted approach to therapeutic relief that can be modulated as well, provisions for integrating various safety mechanisms, and negligible use of opioids / other medications, have captured the interest of several stakeholders in the industry. In fact, since 2010, over 4,000 patents have been published in this domain, indicating the rapid pace at which research is being carried out. It is anticipated that such efforts are likely to boost the overall growth of this market in the coming years.

The ‘Neurostimulation Devices Market (2nd Edition), 2018-2030’ report features an extensive study of the current landscape and future outlook of the growing market for neurostimulation devices. The focus of this study is on invasive neurostimulation devices, such as devices for spinal cord stimulation (SCS), deep brain stimulation (DBS), spinal nerve stimulation (SNS), vagus nerve stimulation (VNS), other cranial nerve stimulation (Other CNS) and other variants of neurostimulation devices. Amongst other elements, the report features:

A detailed assessment of the overall landscape of neurostimulation devices market, featuring the contributions of various companies engaged in this domain and highlighting key device specifications (size, weight, battery type, battery life, number of electrodes, type of programming, and MRI compatibility), along with information on different types of neurostimulation devices, target therapeutic areas, and regulatory approvals received across various geographies.
A comprehensive product competitiveness analysis, taking into consideration the supplier power and specific device-related parameters, such as the number of target indications, target nerves, regulatory approvals, and key device specifications.
Comprehensive profiles of developers of leading neurostimulation devices (shortlisted on the basis of the product competitiveness analysis), featuring an overview of the company, its financial information (if available), and a detailed description of the device(s). Each profile also includes a list of recent developments, highlighting the achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
An elaborate discussion on the regulatory landscape related to medical devices across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan). The information covers details on the payer mix and the reimbursement processes of various public/private organizations across these geographies.
A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands across different device types, taking into consideration several aspects, such as strength / diversity of product portfolio, extent of patent portfolio, recent collaborations, number of target indications and regulatory approvals, and the overall market positioning of the players.
An in-depth analysis of the patents that have been published since 2013. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, IP litigations, emerging areas, leading industry players (in terms of the number of patents filed/granted), and patent benchmarking and valuation.
A comprehensive clinical trial analysis of completed, ongoing and planned studies of various neurostimulation devices. For the purpose of this analysis, we looked at the clinical studies that have been last updated in 2013, and analyzed them on the basis of various parameters, such as current trial status, regional distribution, leading industry and non-industry players, key indications, and enrolled patient population across different geographies.
An analysis of the partnerships that have been established in the recent past, covering product development/commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers/acquisitions, and others.
An analysis of investments made at various stages of product development/commercialization; these include seed financing, venture capital financing, debt financing and grants/awards received by the companies that are operating in this domain.
A comprehensive list of non-invasive neurostimulation devices, along with information on their developers, various types of non-invasive technologies used, target therapeutic areas, and development/approval status of the devices.
An elaborate discussion on the upcoming opportunities/trends in the field of neurostimulation devices that are likely to impact the evolution of this market over the coming years.

One of the key objectives of the report was to estimate the existing market size and potential growth opportunities for neurostimulation devices. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030. The report provides sales forecasts for the overall neurostimulation devices market with detailed market segmentation on the basis of type neurostimulation devices (SCS, DBS, VNS, and other types), indication (chronic pain, dystonia, epilepsy, essential tremor, heart failure, major depressive disorder, Parkinson’s disease, obsessive-compulsive disorder, overactive bladder, sleep apnea), MRI compatibility (MRI compatible and MRI non-compatible), and the geographical distribution of the market (US, Canada, UK, Germany, France, Spain, Italy, Australia, China, and Japan). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in this study were also influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Dave Rosa (President and Chief Executive Officer, NeuroOne Medical Technologies)
Deborah Schmalz (Vice President, Regulatory Affairs, Clinical Research and Compliance, ReShape Lifesciences) and Diane Utzman-O’Neill (Vice President, Marketing, ReShape Lifesciences)
Jan Pieter Heemels (Vice President, Commercial Operations, Mainstay Medical)
Laura Tyler Perryman (Chief Executive Officer, Stimwave)
Luca Ravagnan (Chief Executive Officer, WISE)
Steve Goedeke (President and Chief Executive Officer, Cardionomic)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.

Example Highlights
Over 120 implantable neurostimulation devices are presently available / under development for the treatment of chronic disorders. Of these, close to 31% are spinal cord stimulating (SCS) products indicated for managing different forms of chronic pain. Examples include (in alphabetical order, no specific selection criteria) Algovita®, Altius® System, Intellis™, Precision Spectra™, Proclaim™ Elite, Senza®, and StimRouter®. These are followed by deep brain stimulation (DBS) devices (20%) that are designed to stimulate globus pallidus / subthalamic nucleus, the ventral intermediate of the thalamus and other portions of the brain for the treatment of neurological / movement-related disorders. Other therapeutic areas for which such devices are available / under evaluation include urological disorders, respiratory disorders, cardiovascular disorders, gastrointestinal disorders, sleep disorders and metabolic disorders.

Around 75% of the companies that are involved in the development of neurostimulation devices are small-sized firms/start-ups (fewer than 200 employees). Examples of such players include (in alphabetical order, no specific selection criteria) Cardionomic, Lungpacer Medical, Neuros Medical, Nyxoah, Respicardia, SPR Therapeutics and Stimwave. However, the overall market is currently dominated by a few well-established players that are actively developing/improving their proprietary technologies in order to further increase their footprint in this competitive domain. Examples of such players include (in alphabetical order, no specific selection criteria) Abbott (St. Jude Medical), Boston Scientific, LivaNova, Medtronic and Nevro.
It is worth highlighting that more than 45% approvals have been granted to various neurostimulation devices in the EU, followed by approvals granted by the US FDA, Australian TGA and Health Canada for the treatment of different chronic clinical conditions. In fact, close to 65 marketing approvals have been granted to these devices across different regions since 2015. Examples of devices approved in the year 2018 include (in alphabetical order, no specific selection criteria) Axonics® r-SNM™ System (TGA approval for overactive bladder),SenTiva® (CE Mark for epilepsy), Senza II™ (CE Mark for chronic pain), Spectra WaveWriter™ (US FDA approval for chronic pain), StimGuard’s SNS system (CE Mark for overactive bladder), StimRouter® (Health Canada approval for chronic peripheral nerve pain), and TransAeris™ System (CE Mark for ventilator-induced diaphragm dysfunction).

Close to 45% of the neurostimulation devices feature magnetic resonance (MR) conditional labelling, allowing patients to undergo safe magnetic resonance imaging (MRI) of full body / specific body parts. Further, around 40% of neurostimulation devices utilize rechargeable batteries in their implantable pulse generators (IPGs), while close to 15% of devices have battery-free IPGs in order to deliver minimally invasive therapies to the patients.
Extensive research efforts in this domain have resulted in the publication of over 4,000 patents since 2010. Stakeholders that have filed/been granted the maximum number of patents related to neurostimulation devices in the last 8-10 years include (in decreasing order of the number of patents) Boston Scientific, Medtronic, LivaNova, Abbott (St. Jude Medical), NeuroPace, and Metavention.

Further, close to 1,000 clinical studies have been registered (completed / ongoing / planned) across different geographies. Based on the number of trials, North America (~380 trials) has emerged as a major research/innovation hub in this domain; about 55% of the total number of patients enrolled in the aforementioned trials were reported to have been recruited in centers in this region, followed by Europe and Asia-Pacific. Further, the maximum number (150) of trials evaluating neurostimulation devices were observed to be associated with chronic pain.

Capital investments, totalling USD 1.8 billion have been made across over 100 instances in this domain since 2015. Examples of companies that have received relatively more funding include (in reverse chronological order) Inspire Medical Systems (USD 108 million), Metavention (USD 65 million in 2018), NeuroPace (USD 74 million in 2017), ReShape Lifesciences (USD 61 million in 2017), and CVRx (USD 93 million in 2016), and Nevro (USD 173 million in 2016). Examples of prominent venture capital investors that have actively purchased equity in this domain include (in decreasing order of the number of instances) Action Potential Venture Capital, Atlante Ventures, Gilde Healthcare Partners, Cormorant Asset Management, Andera Partners, F3F, and KCK Group.

The market for neurostimulation devices is expected to grow at an annualized rate of 13.2% between 2018 and 2030. While SCS devices, intended primarily for pain management, are expected to occupy a majority of the share in the market, DBS devices (utilized for the treatment of neuropsychological disorders) are anticipated to grow at a relatively faster rate in the forecast period. Further, the major share (over 75%) of revenues is anticipated to be distributed between North America and Europe; however, we believe that certain Asian countries, such as China, are likely to grow at a faster rate as compared to other regions over the coming decade; this is attributed to the increasing awareness about the nature of these therapies and a less stringent regulatory environment.

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. An Overview of the Nervous System
3.2. Neurological Impairment
3.2.1. Global Burden of Neurological Disorders
3.2.2. Conventional Treatment Methods for Neurological Disorders
3.3. An Overview of Neuromodulation
3.4. Neurostimulation Devices
3.4.1. Historical Development
3.4.2. General Components and Working Principle
3.4.3. Types of Neurostimulation Devices
3.4.3.1. Spinal Cord Stimulation
3.4.3.2. Deep Brain Stimulation
3.4.3.3. Peripheral Nerve Stimulation
3.4.3.3.1. Spinal Nerve Stimulation
3.4.3.3.2. Vagus Nerve Stimulation
3.4.3.3.3. Other Cranial Nerve Stimulation
3.4.3.4. Comparison of Different Types
3.4.4. Advantages and Limitations
3.4.5. Potential Applications
3.4.6. Growth Drivers and Road-blocks
3.5. Social Media Trends Related to Neurostimulation Devices

4. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

4.1. Chapter Overview
4.2. General Regulatory and Reimbursement Guidelines for Medical Devices
4.3. Regulatory and Reimbursement Landscape in North America
4.3.1. The US Scenario
4.3.1.1. Regulatory Authority
4.3.1.2. Review / Approval Process
4.3.1.3. Reimbursement Landscape
4.3.1.3.1. Payer Mix
4.3.1.3.2. Reimbursement Process
4.3.2. The Canadian Scenario
4.3.2.1. Regulatory Authority
4.3.2.2. Review / Approval Process
4.3.2.3. Reimbursement Landscape
4.3.2.3.1. Payer Mix
4.3.2.3.2. Reimbursement Process
4.4. Regulatory and Reimbursement Landscape in Europe
4.4.1. Overall Scenario
4.4.1.1. Regulatory Authority
4.4.1.2. Review / Approval Process
4.4.2. The UK Scenario
4.4.2.1. Reimbursement Landscape
4.4.2.1.1. Payer Mix
4.4.2.1.2. Reimbursement Process
4.4.3. The German Scenario
4.4.3.1. Reimbursement Landscape
4.4.3.1.1. Payer Mix
4.4.3.1.2. Reimbursement Process
4.4.4. The French Scenario
4.4.4.1. Reimbursement Landscape
4.4.4.1.1. Payer Mix
4.4.4.1.2. Reimbursement Process
4.4.5. The Spanish Scenario
4.4.5.1. Reimbursement Landscape
4.4.5.1.1. Payer Mix
4.4.5.1.2. Reimbursement Process
4.4.6. The Italian Scenario
4.4.6.1. Reimbursement Landscape
4.4.6.1.1 Payer Mix
4.4.6.1.2. Reimbursement Process
4.5. Regulatory and Regulatory Landscape in Asia-Pacific
4.5.1. The Australian Scenario
4.5.1.1. Regulatory Authority
4.5.1.2. Review / Approval Process
4.5.1.3. Reimbursement Landscape
4.5.1.3.1. Payer Mix
4.5.1.3.2. Reimbursement Process
4.5.2. The Chinese Scenario
4.5.2.1. Regulatory Authority
4.5.2.2. Review / Approval Process
4.5.2.3. Reimbursement Landscape
4.5.2.3.1. Payer Mix
4.5.2.3.2. Reimbursement Process
4.5.3. The Japanese Scenario
4.5.3.1. Regulatory Authority
4.5.3.2. Review / Approval Process
4.5.3.3. Reimbursement Landscape
4.5.3.3.1. Payer Mix
4.5.3.3.2. Reimbursement Process

5. CURRENT MARKET LANDSCAPE

5.1. Chapter Overview
5.2. Neurostimulation Devices: Overall Market Landscape
5.2.1. Distribution by Year of Establishment
5.2.2. Distribution by Geographical Location
5.2.3. Distribution by Size of Developers
5.2.4. Distribution by Developers
5.2.5. Distribution by Type of Devices
5.2.6. Distribution by Target Nerve
5.2.7. Distribution by Therapeutic Areas
5.2.8. Distribution by Development / Approval Status
5.2.9. Distribution by Size
5.2.10. Distribution by Weight
5.2.11. Distribution by Battery Type
5.2.12. Distribution by Battery Longevity
5.2.13. Distribution by Number of Electrodes
5.2.14. Distribution by MRI Compatibility
5.3. List of Potential Neurostimulation Devices

6. SPINAL CORD STIMULATION

6.1. Chapter Overview
6.2. Overview of SCS Devices
6.2.1. Historical Development
6.2.2. Associated Surgical Procedures
6.2.3. Device Approval Timeline
6.3. Device Competitiveness Analysis
6.4. Key Device Developers
6.4.1. Medtronic
6.4.1.1. Chapter Overview
6.4.1.2. Financial Information
6.4.1.3. Device Description: Intellis™
6.4.1.4. Recent Developments and Future Outlook
6.4.2. Boston Scientific
6.4.2.1. Chapter Overview
6.4.2.2. Financial Information
6.4.2.3. Device Description: Precision™ Plus
6.4.2.4. Recent Developments and Future Outlook
6.4.3. Stimwave
6.4.3.1. Chapter Overview
6.4.3.2. Financial Information
6.4.3.3. Device Description: Freedom-8A, Freedom-4
6.4.3.4. Recent Developments and Future Outlook
6.4.4. Nevro
6.4.4.1. Chapter Overview
6.4.4.2. Financial Information
6.4.4.3. Device Description: Senza®
6.4.4.4. Recent Developments and Future Outlook

7. DEEP BRAIN STIMULATION

7.1. Chapter Overview
7.2. Overview of DBS Devices
7.2.1. Historical Development
7.2.2. Associated Surgical Procedures
7.2.3. Device Approval Timeline
7.3. Device Competitiveness Analysis
7.4. Key Device Developers
7.4.1. Medtronic
7.4.1.1. Chapter Overview
7.4.1.2. Financial Information
7.4.1.3. Device Description: Activa™ PC, Activa™ SC, Activa™ RC
7.4.1.4. Recent Developments and Future Outlook
7.4.2. Boston Scientific
7.4.2.1. Chapter Overview
7.4.2.2. Financial Information
7.4.2.3. Device Description: Vercise™ DBS, Vercise Gevia™
7.4.2.4. Recent Developments and Future Outlook
7.4.3. Beijing PINS Medical
7.4.3.1. Chapter Overview
7.4.3.2. Financial Information
7.4.3.3. Device Description: PINS™ DBS System
7.4.3.4. Recent Developments and Future Outlook
7.4.4. Abbott (St. Jude Medical)
7.4.4.1. Chapter Overview
7.4.4.2. Financial Information
7.4.4.3. Device Description: Brio™
7.4.4.4. Recent Developments and Future Outlook

8. PERIPHERAL NERVE STIMULATION

8.1. Chapter Overview
8.2. Overview of PNS Devices
8.2.1. Historical Development
8.2.2. Associated Surgical Procedures
8.2.3. Device Approval Timeline
8.3. Spinal Nerve Stimulation
8.3.1. Device Competitiveness Analysis
8.3.2. Key Device Developers
8.3.2.1. Axonics Modulation Technologies
8.3.2.1.1. Chapter Overview
8.3.2.1.2. Financial Information
8.3.2.1.3. Device Description: Axonics® r-SNM™ System
8.3.2.1.4. Recent Developments and Future Outlook
8.3.2.2. BrainsGate
8.3.2.2.1. Chapter Overview
8.3.2.2.2. Financial Information
8.3.2.2.3. Device Description: Ischemic Stroke System™
8.3.2.2.4. Recent Developments and Future Outlook
8.3.2.3. Medtronic
8.3.2.3.1. Chapter Overview
8.3.2.3.2. Financial Information
8.3.2.3.3. Device Description: InterStim II
8.3.2.3.4. Recent Developments and Future Outlook
8.4. Vagus Nerve Stimulation
8.4.1. Device Competitiveness Analysis
8.4.2. Key Device Developers
8.4.2.1. LivaNova
8.4.2.1.1. Chapter Overview
8.4.2.1.2. Financial Information
8.4.2.1.3. Device Description: Pulse, Pulse Duo, AspireHC®, AspireSR®, SenTiva®
8.4.2.1.4. Recent Developments and Future Outlook
8.4.2.2. SetPoint Medical
8.4.2.2.1. Chapter Overview
8.4.2.2.2. Financial Information
8.4.2.2.3. Device Description: Unnamed Bioelectronic Platform
8.4.2.2.4. Recent Developments and Future Outlook
8.4.2.3. Synergia Medical
8.4.2.3.1. Chapter Overview
8.4.2.3.2. Financial Information
8.4.2.3.3. Device Description: NAOS Platform
8.4.2.3.4. Recent Developments and Future Outlook
8.5. Other Cranial Nerve Stimulation
8.5.1. Device Competitiveness Analysis
8.5.2. Key Device Developers
8.5.2.1. Bioness
8.5.2.1.1. Chapter Overview
8.5.2.1.2. Financial Information
8.5.2.1.3. Device Description: StimRouter®
8.5.2.1.4. Recent Developments and Future Outlook
8.5.2.2. Medtronic
8.5.2.2.1. Chapter Overview
8.5.2.2.2. Financial Information
8.5.2.2.3. Device Description: Intellis™
8.5.2.2.4. Recent Developments and Future Outlook
8.5.2.3. Nyxoah
8.5.2.3.1. Chapter Overview
8.5.2.3.2. Financial Information
8.5.2.3.3. Device Description: Genio™
8.5.2.3.4. Recent Developments and Future Outlook
8.5.2.4. BlueWind Medical
8.5.2.4.1. Chapter Overview
8.5.2.4.2. Financial Information
8.5.2.4.3. Device Description: RENOVA™, VIVENDI™
8.5.2.4.4. Recent Developments and Future Outlook

9. BRAND POSITIONING ANALYSIS

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Brand Positioning Matrices of Key Industry Players
9.3.1. Abbott (St. Jude Medical)
9.3.2. Boston Scientific
9.3.3. LivaNova
9.3.4. Medtronic
9.3.5. Stimwave

10. PATENT ANALYSIS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Neurostimulation Devices: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Geographical Location
10.3.3. Analysis by CPC Classifications
10.3.4. Emerging Areas
10.3.5. Leading Players by Number of Patents
10.4. Neurostimulation Devices: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.1.1. Boston Scientific and Medtronic
10.4.1.2. Other Leading Patent Assignees
10.4.2. Analysis by Geographical Distribution
10.5. Neurostimulation Devices: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations

11. CLINICAL TRIAL ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Neurostimulation Devices: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Geography and Number of Clinical Trials
11.3.3. Analysis by Geography and Enrolled Patient Population
11.3.4. Analysis by Trial Recruitment Status
11.3.5. Analysis by Type of Sponsors / Collaborators
11.3.6. Most Active Players in terms of Number of Trials
11.3.7. Analysis by Focus Area of Trials
11.3.8. Leading Indications in terms of Number of Trials

12. COLLABORATIONS AND PARTNERSHIPS

12.1. Chapter Overview
12.2. Partnership Models
12.3. Neurostimulation Devices: Recent Collaborations and Partnerships
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of Device
12.3.4. Most Active Players by Number of Partnerships
12.3.5. Analysis by Geographical Regions
12.3.5.1. Most Active Players
12.3.5.2. Intercontinental and Intracontinental Agreements

13. FUNDING AND INVESTMENT ANALYSIS

13.1. Chapter Overview
13.2. Types of Funding
13.3. Neurostimulation Devices: Funding and Investment Instances
13.3.1. Analysis by Number of Funding Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Most Popular Device Types by Number of Funding Instances and Amount Invested
13.3.5. Most Active Players
13.3.6. Most Active Investors
13.4. Concluding Remarks

14. MARKET FORECAST

14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Neurostimulation Devices Market
14.3.1. Global Neurostimulation Devices Market, 2018-2030 (By Value)
14.3.2. Global Neurostimulation Devices Market, 2018-2030 (By Volume)
14.4. Global Neurostimulation Devices Market: Distribution by Type of Device, Indication and Geography
14.4.1. Global SCS Devices Market, 2018-2030 (By Value)
14.4.1.1. Global SCS Devices Market for Chronic Pain, 2018-2030 (By Value)
14.4.1.1.1. SCS Devices Market for Chronic Pain in the US, 2018-2030 (By Value)
14.4.1.1.2. SCS Devices Market for Chronic Pain in Canada, 2018-2030 (By Value)
14.4.1.1.3. SCS Devices Market for Chronic Pain in the UK, 2018-2030 (By Value)
14.4.1.1.4. SCS Devices Market for Chronic Pain in Germany, 2018-2030 (By Value)
14.4.1.1.5. SCS Devices Market for Chronic Pain in France, 2018-2030 (By Value)
14.4.1.1.6. SCS Devices Market for Chronic Pain in Spain, 2018-2030 (By Value)
14.4.1.1.7. SCS Devices Market for Chronic Pain in Italy, 2018-2030 (By Value)
14.4.1.1.8. SCS Devices Market for Chronic Pain in Australia, 2018-2030 (By Value)
14.4.1.1.9. SCS Devices Market for Chronic Pain in China, 2018-2030 (By Value)
14.4.1.1.10. SCS Devices Market for Chronic Pain in Japan, 2018-2030 (By Value)
14.4.2. Global SCS Devices Market, 2018-2030 (By Volume)
14.4.2.1. Global SCS Devices Market for Chronic Pain, 2018-2030 (By Volume)
14.4.2.1.1. SCS Devices Market for Chronic Pain in the US, 2018-2030 (By Volume)
14.4.2.1.2. SCS Devices Market for Chronic Pain in Canada, 2018-2030 (By Volume)
14.4.2.1.3. SCS Devices Market for Chronic Pain in the UK, 2018-2030 (By Volume)
14.4.2.1.4. SCS Devices Market for Chronic Pain in Germany, 2018-2030 (By Volume)
14.4.2.1.5. SCS Devices Market for Chronic Pain in France, 2018-2030 (By Volume)
14.4.2.1.6. SCS Devices Market for Chronic Pain in Spain, 2018-2030 (By Volume)
14.4.2.1.7. SCS Devices Market for Chronic Pain in Italy, 2018-2030 (By Volume)
14.4.2.1.8. SCS Devices Market for Chronic Pain in Australia, 2018-2030 (By Volume)
14.4.2.1.9. SCS Devices Market for Chronic Pain in China, 2018-2030 (By Volume)
14.4.2.1.10. SCS Devices Market for Chronic Pain in Japan, 2018-2030 (By Volume)
14.4.3. Global DBS Devices Market, 2018-2030 (By Value)
14.4.3.1. Global DBS Devices Market for Essential Tremor, 2018-2030 (By Value)
14.4.3.1.1. DBS Devices Market for Essential Tremor in the US, 2018-2030 (By Value)
14.4.3.1.2. DBS Devices Market for Essential Tremor in Canada, 2018-2030 (By Value)
14.4.3.1.3. DBS Devices Market for Essential Tremor in the UK, 2018-2030 (By Value)
14.4.3.1.4. DBS Devices Market for Essential Tremor in Germany, 2018-2030 (By Value)
14.4.3.1.5. DBS Devices Market for Essential Tremor in France, 2018-2030 (By Value)
14.4.3.1.6. DBS Devices Market for Essential Tremor in Spain, 2018-2030 (By Value)
14.4.3.1.7. DBS Devices Market for Essential Tremor in Italy, 2018-2030 (By Value)
14.4.3.1.8. DBS Devices Market for Essential Tremor in Australia, 2018-2030 (By Value)
14.4.3.1.9. DBS Devices Market for Essential Tremor in China, 2018-2030 (By Value)
14.4.3.1.10. DBS Devices Market for Essential Tremor in Japan, 2018-2030 (By Value)
14.4.3.2. Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (By Value)
14.4.3.2.1. DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (By Value)
14.4.3.2.2. DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (By Value)
14.4.3.2.3. DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (By Value)
14.4.3.2.4. DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (By Value)
14.4.3.2.5. DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (By Value)
14.4.3.2.6. DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (By Value)
14.4.3.2.7. DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (By Value)
14.4.3.2.8. DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (By Value)
14.4.3.2.9. DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (By Value)
14.4.3.2.10. DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (By Value)
14.4.3.3. Global DBS Devices Market for Dystonia, 2018-2030 (By Value)
14.4.3.3.1. DBS Devices Market for Dystonia in the US, 2018-2030 (By Value)
14.4.3.3.2. DBS Devices Market for Dystonia in Canada, 2018-2030 (By Value)
14.4.3.3.3. DBS Devices Market for Dystonia in the UK, 2018-2030 (By Value)
14.4.3.3.4. DBS Devices Market for Dystonia in Germany, 2018-2030 (By Value)
14.4.3.3.5. DBS Devices Market for Dystonia in France, 2018-2030 (By Value)
14.4.3.3.6. DBS Devices Market for Dystonia in Spain, 2018-2030 (By Value)
14.4.3.3.7. DBS Devices Market for Dystonia in Italy, 2018-2030 (By Value)
14.4.3.3.8. DBS Devices Market for Dystonia in Australia, 2018-2030 (By Value)
14.4.3.3.9. DBS Devices Market for Dystonia in China, 2018-2030 (By Value)
14.4.3.3.10. DBS Devices Market for Dystonia in Japan, 2018-2030 (By Value)
14.4.3.4. Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (By Value)
14.4.3.4.1. DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (By Value)
14.4.3.4.2. DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (By Value)
14.4.3.4.3. DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (By Value)
14.4.3.4.4. DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (By Value)
14.4.3.4.5. DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (By Value)
14.4.3.4.6. DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (By Value)
14.4.3.4.7. DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (By Value)
14.4.3.4.8. DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (By Value)
14.4.3.4.9. DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (By Value)
14.4.3.4.10. DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (By Value)
14.4.4. Global DBS Devices Market, 2018-2030 (By Volume)
14.4.4.1. Global DBS Devices Market for Essential Tremor, 2018-2030 (By Volume)
14.4.4.1.1. DBS Devices Market for Essential Tremor in the US, 2018-2030 (By Volume)
14.4.4.1.2. DBS Devices Market for Essential Tremor in Canada, 2018-2030 (By Volume)
14.4.4.1.3. DBS Devices Market for Essential Tremor in the UK, 2018-2030 (By Volume)
14.4.4.1.4. DBS Devices Market for Essential Tremor in Germany, 2018-2030 (By Volume)
14.4.4.1.5. DBS Devices Market for Essential Tremor in France, 2018-2030 (By Volume)
14.4.4.1.6. DBS Devices Market for Essential Tremor in Spain, 2018-2030 (By Volume)
14.4.4.1.7. DBS Devices Market for Essential Tremor in Italy, 2018-2030 (By Volume)
14.4.4.1.8. DBS Devices Market for Essential Tremor in Australia, 2018-2030 (By Volume)
14.4.4.1.9. DBS Devices Market for Essential Tremor in China, 2018-2030 (By Volume)
14.4.4.1.10. DBS Devices Market for Essential Tremor in Japan, 2018-2030 (By Volume)
14.4.4.2. Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (By Volume)
14.4.4.2.1. DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (By Volume)
14.4.4.2.2. DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (By Volume)
14.4.4.2.3. DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (By Volume)
14.4.4.2.4. DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (By Volume)
14.4.4.2.5. DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (By Volume)
14.4.4.2.6. DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (By Volume)
14.4.4.2.7. DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (By Volume)
14.4.4.2.8. DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (By Volume)
14.4.4.2.9. DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (By Volume)
14.4.4.2.10. DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (By Volume)
14.4.4.3. Global DBS Devices Market for Dystonia, 2018-2030 (By Volume)
14.4.4.3.1. DBS Devices Market for Dystonia in the US, 2018-2030 (By Volume)
14.4.4.3.2. DBS Devices Market for Dystonia in Canada, 2018-2030 (By Volume)
14.4.4.3.3. DBS Devices Market for Dystonia in the UK, 2018-2030 (By Volume)
14.4.4.3.4. DBS Devices Market for Dystonia in Germany, 2018-2030 (By Volume)
14.4.4.3.5. DBS Devices Market for Dystonia in France, 2018-2030 (By Volume)
14.4.4.3.6. DBS Devices Market for Dystonia in Spain, 2018-2030 (By Volume)
14.4.4.3.7. DBS Devices Market for Dystonia in Italy, 2018-2030 (By Volume)
14.4.4.3.8. DBS Devices Market for Dystonia in Australia, 2018-2030 (By Volume)
14.4.4.3.9. DBS Devices Market for Dystonia in China, 2018-2030 (By Volume)
14.4.4.3.10. DBS Devices Market for Dystonia in Japan, 2018-2030 (By Volume)
14.4.4.4. Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (By Volume)
14.4.4.4.1. DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (By Volume)
14.4.4.4.2. DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (By Volume)
14.4.4.4.3. DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (By Volume)
14.4.4.4.4. DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (By Volume)
14.4.4.4.5. DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (By Volume)
14.4.4.4.6. DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (By Volume)
14.4.4.4.7. DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (By Volume)
14.4.4.4.8. DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (By Volume)
14.4.4.4.9. DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (By Volume)
14.4.4.4.10. DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (By Volume)
14.4.5. Global VNS Devices Market, 2018-2030 (By Value)
14.4.5.1. Global VNS Devices Market for Epilepsy, 2018-2030 (By Value)
14.4.5.1.1. VNS Devices Market for Epilepsy in the US, 2018-2030 (By Value)
14.4.5.1.2. VNS Devices Market for Epilepsy in Canada, 2018-2030 (By Value)
14.4.5.1.3. VNS Devices Market for Epilepsy in the UK, 2018-2030 (By Value)
14.4.5.1.4. VNS Devices Market for Epilepsy in Germany, 2018-2030 (By Value)
14.4.5.1.5. VNS Devices Market for Epilepsy in France, 2018-2030 (By Value)
14.4.5.1.6. VNS Devices Market for Epilepsy in Spain, 2018-2030 (By Value)
14.4.5.1.7. VNS Devices Market for Epilepsy in Italy, 2018-2030 (By Value)
14.4.5.1.8. VNS Devices Market for Epilepsy in Australia, 2018-2030 (By Value)
14.4.5.1.9. VNS Devices Market for Epilepsy in China, 2018-2030 (By Value)
14.4.5.1.10. VNS Devices Market for Epilepsy in Japan, 2018-2030 (By Value)
14.4.5.2. Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (By Value)
14.4.5.2.1. VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (By Value)
14.4.5.2.2. VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (By Value)
14.4.5.2.3. VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (By Value)
14.4.5.2.4. VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (By Value)
14.4.5.2.5. VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (By Value)
14.4.5.2.6. VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (By Value)
14.4.5.2.7. VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (By Value)
14.4.5.2.8. VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (By Value)
14.4.5.2.9. VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (By Value)
14.4.5.2.10. VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (By Value)
14.4.6. Global VNS Devices Market, 2018-2030 (By Volume)
14.4.6.1. Global VNS Devices Market for Epilepsy, 2018-2030 (By Volume)
14.4.6.1.1. VNS Devices Market for Epilepsy in the US, 2018-2030 (By Volume)
14.4.6.1.2. VNS Devices Market for Epilepsy in Canada, 2018-2030 (By Volume)
14.4.6.1.3. VNS Devices Market for Epilepsy in the UK, 2018-2030 (By Volume)
14.4.6.1.4. VNS Devices Market for Epilepsy in Germany, 2018-2030 (By Volume)
14.4.6.1.5. VNS Devices Market for Epilepsy in France, 2018-2030 (By Volume)
14.4.6.1.6. VNS Devices Market for Epilepsy in Spain, 2018-2030 (By Volume)
14.4.6.1.7. VNS Devices Market for Epilepsy in Italy, 2018-2030 (By Volume)
14.4.6.1.8. VNS Devices Market for Epilepsy in Australia, 2018-2030 (By Volume)
14.4.6.1.9. VNS Devices Market for Epilepsy in China, 2018-2030 (By Volume)
14.4.6.1.10. VNS Devices Market for Epilepsy in Japan, 2018-2030 (By Volume)
14.4.6.2. Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (By Volume)
14.4.6.2.1. VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (By Volume)
14.4.6.2.2. VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (By Volume)
14.4.6.2.3. VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (By Volume)
14.4.6.2.4. VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (By Volume)
14.4.6.2.5. VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (By Volume)
14.4.6.2.6. VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (By Volume)
14.4.6.2.7. VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (By Volume)
14.4.6.2.8. VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (By Volume)
14.4.6.2.9. VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (By Volume)
14.4.6.2.10. VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (By Volume)
14.4.7. Global Other Neurostimulation Devices Market, 2018-2030 (By Value)
14.4.7.1. Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (By Value)
14.4.7.1.1. Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (By Value)
14.4.7.1.2. Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (By Value)
14.4.7.1.3. Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (By Value)
14.4.7.1.4. Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (By Value)
14.4.7.1.5. Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (By Value)
14.4.7.1.6. Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (By Value)
14.4.7.1.7. Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (By Value)
14.4.7.1.8. Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (By Value)
14.4.7.1.9. Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (By Value)
14.4.7.1.10. Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (By Value)
14.4.7.2. Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (By Value)
14.4.7.2.1. Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (By Value)
14.4.7.2.2. Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (By Value)
14.4.7.2.3. Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (By Value)
14.4.7.2.4. Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (By Value)
14.4.7.2.5. Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (By Value)
14.4.7.2.6. Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (By Value)
14.4.7.2.7. Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (By Value)
14.4.7.2.8. Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (By Value)
14.4.7.2.9. Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (By Value)
14.4.7.2.10. Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (By Value)
14.4.7.3. Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (By Value)
14.4.7.3.1. Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (By Value)
14.4.7.3.2. Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (By Value)
14.4.7.3.3. Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (By Value)
14.4.7.3.4. Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (By Value)
14.4.7.3.5. Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (By Value)
14.4.7.3.6. Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (By Value)
14.4.7.3.7. Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (By Value)
14.4.7.3.8. Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (By Value)
14.4.7.3.9. Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (By Value)
14.4.7.3.10. Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (By Value)
14.4.8. Global Other Neurostimulation Devices Market, 2018-2030 (By Volume)
14.4.8.1. Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (By Volume)
14.4.8.1.1. Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (By Volume)
14.4.8.1.2. Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (By Volume)
14.4.8.1.3. Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (By Volume)
14.4.8.1.4. Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (By Volume)
14.4.8.1.5. Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (By Volume)
14.4.8.1.6. Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (By Volume)
14.4.8.1.7. Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (By Volume)
14.4.8.1.8. Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (By Volume)
14.4.8.1.9. Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (By Volume)
14.4.8.1.10. Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (By Volume)
14.4.8.2. Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (By Volume)
14.4.8.2.1. Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (By Volume)
14.4.8.2.2. Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (By Volume)
14.4.8.2.3. Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (By Volume)
14.4.8.2.4. Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (By Volume)
14.4.8.2.5. Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (By Volume)
14.4.8.2.6. Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (By Volume)
14.4.8.2.7. Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (By Volume)
14.4.8.2.8. Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (By Volume)
14.4.8.2.9. Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (By Volume)
14.4.8.2.10. Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (By Volume)
14.4.8.3. Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (By Volume)
14.4.8.3.1. Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (By Volume)
14.4.8.3.2. Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (By Volume)
14.4.8.3.3. Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (By Volume)
14.4.8.3.4. Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (By Volume)
14.4.8.3.5. Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (By Volume)
14.4.8.3.6. Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (By Volume)
14.4.8.3.7. Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (By Volume)
14.4.8.3.8. Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (By Volume)
14.4.8.3.9. Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (By Volume)
14.4.8.3.10. Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (By Volume)
14.5. Global Neurostimulation Devices Market: Distribution by MRI Compatibility
14.5.1. Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (By Value)
14.5.2. Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (By Volume)
14.5.3. Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (By Volume)
14.5.4. Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (By Volume)

15. FUTURE GROWTH OPPORTUNITIES

15.1. Chapter Overview
15.2. Development of Devices to Address the Needs of Unexplored Therapeutic Areas
15.3. Integration of Novel and Advanced Features in Devices
15.4. Launch / Commercialization of Devices Across Different Geographies
15.5. Increased Utilization of Real World Data Based Insights to Optimize Device Performance and Support Regulatory / Reimbursement Decisions
15.6. Implementation of Cybersecurity Measures to Tackle Device Hacks

16. EXECUTIVE INSIGHTS

16.1. Chapter Overview
16.2. NeuroOne Medical Technologies
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Dave Rosa, President and Chief Executive Officer
16.3. ReShape Lifesciences
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Deborah Schmalz, Vice President, Regulatory Affairs, Clinical Research and Compliances, and Diane Utzman-O'Neill, Vice President, Marketing
16.4. Mainstay Medical
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Jan Pieter Heemels, Vice President, Commercial Operations
16.5. Stimwave
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Laura Tyler Perryman, Chief Executive Officer
16.6. WISE
16.6.1. Company Snapshot
16.6.2. Interview Transcript: Luca Ravagnan, Chief Executive Officer
16.7. Cardionomic
16.7.1. Company Snapshot
16.7.2. Interview Transcript: Steve Goedeke, President and Chief Executive Officer

17. APPENDIX 1: LIST OF NON-INVASIVE NEUROSTIMULATION DEVICES18. APPENDIX 2: TABULATED DATA19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Common Types of Neurological Disorders
Figure 3.2 DALYs and Deaths from Selected Neurological Disorders, 2015
Figure 3.3 Conventional Treatment Methods for Neurological Disorders
Figure 3.4 Historical Evolution of Neurostimulation Devices
Figure 3.5 Types of Neurostimulation Devices
Figure 3.6 Applications of Neurostimulation Devices
Figure 3.7 Growth Drivers and Roadblocks Related to Neurostimulation Devices
Figure 3.8 Neurostimulation Devices: Social Media Trends
Figure 4.1. US FDA: Review / Approval Process
Figure 4.2. Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 4.3. National Coverage Determination Process in the US
Figure 4.4. Health Canada: Review / Approval Process
Figure 4.5. CE Mark: Review / Approval Process
Figure 4.6. Healthcare Insurance Coverage in the UK: Distribution by Type of Funding Sources
Figure 4.7. Reimbursement Process in the UK
Figure 4.8. Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 4.9. Reimbursement Process in Germany (In-patient Setting)
Figure 4.10. Reimbursement Process in Germany (Out-patient Setting)
Figure 4.11. Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 4.12. Reimbursement Process in France
Figure 4.13. Healthcare Insurance Coverage in Spain: Distribution by Type of Funding Sources
Figure 4.14. Reimbursement Process in Spain
Figure 4.15. Healthcare Insurance Coverage in Italy: Distribution by Type of Funding Sources
Figure 4.16. Reimbursement Process in Italy
Figure 4.17. TGA: Review / Approval Process
Figure 4.18. CFDA: Review / Approval Process
Figure 4.19. PMDA: Review / Approval Process
Figure 5.1 Neurostimulation Devices: Recent Activities
Figure 5.2 Neurostimulation Devices: Distribution of Industry Players by Year of Establishment
Figure 5.3 Neurostimulation Devices: Distribution of Industry Players by Geographical Location
Figure 5.4 Neurostimulation Devices: Distribution of Industry Players by Size (Employee Count)
Figure 5.5 Neurostimulation Devices: Leading Developers in terms of Number of Devices
Figure 5.6 Neurostimulation Devices: Distribution by Type of Devices
Figure 5.7 Neurostimulation Devices: Distribution by Type of Target Nerves
Figure 5.8 Neurostimulation Devices: Leading Target Indications in terms of Number of Devices
Figure 5.9 Neurostimulation Devices: Grid Analysis, Distribution by Device Approval Year, Target Therapeutic Area and Type of Device
Figure 5.10 Neurostimulation Devices: Distribution by Type of Regulatory Approval
Figure 5.11 Neurostimulation Devices: Distribution by Size
Figure 5.12 Neurostimulation Devices: Distribution by Weight
Figure 5.13 Neurostimulation Devices: Distribution by Battery Type
Figure 5.14 Neurostimulation Devices: Distribution by Battery Longevity
Figure 5.15 Neurostimulation Devices: Distribution by Number of Electrodes
Figure 5.16 Neurostimulation Devices: Distribution by MRI Compatibility
Figure 6.1. SCS Devices: Approval Timeline
Figure 6.2. SCS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 6.3. Medtronic: Revenues, FY 2014-FY 2018 (USD Billion)
Figure 6.4. Medtronic, Revenues: Distribution by Business Segments, FY 2018 (USD Billion)
Figure 6.5. Medtronic, Revenues: Distribution by Regions, FY 2018 (USD Billion)
Figure 6.6. Boston Scientific: Revenues, FY 2013-H1 FY 2018 (USD Billion)
Figure 6.7. Boston Scientific, Revenues: Distribution by Business Segments, FY 2017 (USD Billion)
Figure 6.8. Boston Scientific, Revenues: Distribution by Regions, FY 2017 (USD Billion)
Figure 6.9. Nevro: Revenues, FY 2013-Q1 FY 2018 (USD Million)
Figure 6.10. Nevro, Revenues: Distribution by Regions, FY 2017 (USD Million)
Figure 7.1. DBS Devices: Approval Timeline
Figure 7.2. DBS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 7.3. Abbott: Revenues, FY 2013-H1 FY 2018 (USD Billion)
Figure 7.4. Abbott, Revenues: Distribution by Business Segments, FY 2017 (USD Billion)
Figure 7.5. Abbott, Revenues: Distribution by Regions, FY 2017 (USD Billion)
Figure 8.1. PNS Devices: Approval Timeline
Figure 8.2. SNS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 8.3. VNS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 8.4. LivaNova: Revenues, FY 2015-Q1 FY 2018 (USD Million)
Figure 8.5. LivaNova, Revenues: Distribution by Business Segments, FY 2017 (USD Million)
Figure 8.6. LivaNova, Revenues: Distribution by Regions, FY 2017 (USD Million)
Figure 8.7. Other CNS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 9.1 Brand Positioning Analysis of Key Industry Players
Figure 9.2 Brand Positioning Matrix: Abbott (St. Jude Medical)
Figure 9.3 Brand Positioning Matrix: Boston Scientific
Figure 9.4 Brand Positioning Matrix: LivaNova
Figure 9.5 Brand Positioning Matrix: Medtronic
Figure 9.6 Brand Positioning Matrix: Stimwave
Figure 10.1 Patents: Distribution by Type
Figure 10.2 Patents: Cumulative Trend by Publication Year
Figure 10.3 Patents: Distribution by Geographical Location
Figure 10.4 Patents: Distribution by CPC Classifications (Top 20)
Figure 10.5 Patents: Emerging Areas
Figure 10.6 Patents: Distribution by Leading Players
Figure 10.7 Boston Scientific and Medtronic: Benchmarking by Patent Characteristics
Figure 10.8 Other Leading Patent Assignees: Benchmarking by Patent Characteristics
Figure 10.9 Industry Players: Benchmarking by Number of Patents Published Across Different Geographies
Figure10.10 Industry Players: Benchmarking by Number of International Patents
Figure 10.11 Patents: Distribution by Age (January 2010-June 2018)
Figure 10.12 Patent Valuation
Figure 11.1 Clinical Trials: Distribution by Trial Status
Figure 11.2 Clinical Trials: Distribution by Registration Year
Figure 11.3 Clinical Trials: Geographical Distribution by Number of Trials
Figure 11.4 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Figure 11.5 Clinical Trials: Distribution by Registration Year and Recruitment Status
Figure 11.6 Clinical Trials: Geographical Distribution by Registration Year and Recruitment Status
Figure 11.7 Clinical Trials: Distribution by Type of Sponsors / Collaborators
Figure 11.8 Clinical Trials: Most Active Industry Players in terms of Number of Trials Conducted
Figure 11.9 Clinical Trials: Most Active Non-Industry Players in terms of Number of Trials Conducted
Figure 11.10 Clinical Trials: Focus Areas
Figure 11.11 Clinical Trials: Leading Indications in terms of Number of Trials
Figure 11.12 Clinical Trials: Year-wise Trend of Top Five Indications
Figure 12.1 Recent Partnerships: Cumulative Half Year-wise Trend (2015–H1 2018)
Figure 12.2 Recent Partnerships: Distribution by Type of Model
Figure 12.3 Recent Partnerships: Distribution by Year of Partnership and Type of Model
Figure 12.4 Recent Partnerships: Distribution by Type of Device
Figure 12.5 Recent Partnerships: Distribution by Year of Partnership and Type of Device
Figure 12.6 Recent Partnerships: Most Active Players
Figure 12.7 Recent Partnerships: Regional Distribution and Most Active Players
Figure 12.8 Recent Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Figure 13.1 Funding Instances: Cumulative Half Year-wise trend, January 2015-June 2018
Figure 13.2 Funding Instances: Cumulative Amount Invested, January 2015-June 2018 (USD Million)
Figure 13.3 Funding Instances: Distribution by Type of Funding, January 2015-June 2018
Figure 13.4 Funding Instances: Distribution by Amount Invested and Type of Funding, January 2015-June 2018 (USD Million)
Figure 13.5 Summary of Investments, January 2015-June 2018 (USD Million)
Figure 13.6 Funding Instances: Most Popular Device Types by Number of Instances, January 2015-June 2018
Figure 13.7 Funding Instances: Most Popular Device Types by Amount Invested, January 2015-June 2018 (USD Million)
Figure 13.8 Funding Instances: Distribution by Year of Investment and Type of Device, January 2015-June 2018 (USD Million)
Figure 13.9 Funding Instances: Most Active Players in terms of Number of Instances, January 2015-June 2018
Figure 13.10 Funding Instances: Most Active Players in terms of Amount Invested, January 2015-June 2018
Figure 13.11 Funding Instances: Most Active Investors in terms of Number of Instances, January 2015-June 2018
Figure 13.12 Funding Instances: Funding and Investment Summary
Figure 14.1 Global Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.2 Global Neurostimulation Devices Market, 2018-2030 (Units, Volume)
Figure 14.3 Global SCS Devices Market, 2018-2030 (USD Million)
Figure 14.4 Global SCS Devices Market for Chronic Pain, 2018-2030 (USD Million)
Figure 14.5 SCS Devices Market for Chronic Pain in the US, 2018-2030 (USD Million)
Figure 14.6 SCS Devices Market for Chronic Pain in Canada, 2018-2030 (USD Million)
Figure 14.7 SCS Devices Market for Chronic Pain in the UK, 2018-2030 (USD Million)
Figure 14.8 SCS Devices Market for Chronic Pain in Germany, 2018-2030 (USD Million)
Figure 14.9 SCS Devices Market for Chronic Pain in France, 2018-2030 (USD Million)
Figure 14.10 SCS Devices Market for Chronic Pain in Spain, 2018-2030 (USD Million)
Figure 14.11 SCS Devices Market for Chronic Pain in Italy, 2018-2030 (USD Million)
Figure 14.12 SCS Devices Market for Chronic Pain in Australia, 2018-2030 (USD Million)
Figure 14.13 SCS Devices Market for Chronic Pain in China, 2018-2030 (USD Million)
Figure 14.14 SCS Devices Market for Chronic Pain in Japan, 2018-2030 (USD Million)
Figure 14.15 Global SCS Devices Market, 2018-2030 (Units, Volume)
Figure 14.16 Global SCS Devices Market for Chronic Pain, 2018-2030 (Units, Volume)
Figure 14.17 SCS Devices Market for Chronic Pain in the US, 2018-2030 (Units, Volume)
Figure 14.18 SCS Devices Market for Chronic Pain in Canada, 2018-2030 (Units, Volume)
Figure 14.19 SCS Devices Market for Chronic Pain in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.20 SCS Devices Market for Chronic Pain in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.21 SCS Devices Market for Chronic Pain in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.22 SCS Devices Market for Chronic Pain in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.23 SCS Devices Market for Chronic Pain in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.24 SCS Devices Market for Chronic Pain in Australia, 2018-2030 (Units, Volume)
Figure 14.25 SCS Devices Market for Chronic Pain in China, 2018-2030 (Units, Volume)
Figure 14.26 SCS Devices Market for Chronic Pain in Japan, 2018-2030 (Units, Volume)
Figure 14.27 Global DBS Devices Market, 2018-2030 (USD Million)
Figure 14.28 Global DBS Devices Market for Essential Tremor, 2018-2030 (USD Million)
Figure 14.29 DBS Devices Market for Essential Tremor in the US, 2018-2030 (USD Million)
Figure 14.30 DBS Devices Market for Essential Tremor in Canada, 2018-2030 (USD Million)
Figure 14.31 DBS Devices Market for Essential Tremor in the UK, 2018-2030 (USD Million)
Figure 14.32 DBS Devices Market for Essential Tremor in Germany, 2018-2030 (USD Million)
Figure 14.33 DBS Devices Market for Essential Tremor in France, 2018-2030 (USD Million)
Figure 14.34 DBS Devices Market for Essential Tremor in Spain, 2018-2030 (USD Million)
Figure 14.35 DBS Devices Market for Essential Tremor in Italy, 2018-2030 (USD Million)
Figure 14.36 DBS Devices Market for Essential Tremor in Australia, 2018-2030 (USD Million)
Figure 14.37 DBS Devices Market for Essential Tremor in China, 2018-2030 (USD Million)
Figure 14.38 DBS Devices Market for Essential Tremor in Japan, 2018-2030 (USD Million)
Figure 14.39 Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (USD Million)
Figure 14.40 DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (USD Million)
Figure 14.41 DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (USD Million)
Figure 14.42 DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (USD Million)
Figure 14.43 DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (USD Million)
Figure 14.44 DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (USD Million)
Figure 14.45 DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (USD Million)
Figure 14.46 DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (USD Million)
Figure 14.47 DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (USD Million)
Figure 14.48 DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (USD Million)
Figure 14.49 DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (USD Million)
Figure 14.50 Global DBS Devices Market for Dystonia, 2018-2030 (USD Million)
Figure 14.51 DBS Devices Market for Dystonia in the US, 2018-2030 (USD Million)
Figure 14.52 DBS Devices Market for Dystonia in Canada, 2018-2030 (USD Million)
Figure 14.53 DBS Devices Market for Dystonia in the UK, 2018-2030 (USD Million)
Figure 14.54 DBS Devices Market for Dystonia in Germany, 2018-2030 (USD Million)
Figure 14.55 DBS Devices Market for Dystonia in France, 2018-2030 (USD Million)
Figure 14.56 DBS Devices Market for Dystonia in Spain, 2018-2030 (USD Million)
Figure 14.57 DBS Devices Market for Dystonia in Italy, 2018-2030 (USD Million)
Figure 14.58 DBS Devices Market for Dystonia in Australia, 2018-2030 (USD Million)
Figure 14.59 DBS Devices Market for Dystonia in China, 2018-2030 (USD Million)
Figure 14.60 DBS Devices Market for Dystonia in Japan, 2018-2030 (USD Million)
Figure 14.61 Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (USD Million)
Figure 14.62 DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (USD Million)
Figure 14.63 DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (USD Million)
Figure 14.64 DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (USD Million)
Figure 14.65 DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (USD Million)
Figure 14.66 DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (USD Million)
Figure 14.67 DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (USD Million)
Figure 14.68 DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (USD Million)
Figure 14.69 DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (USD Million)
Figure 14.70 DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (USD Million)
Figure 14.71 DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (USD Million)
Figure 14.72 Global DBS Devices Market, 2018-2030 (Units, Volume)
Figure 14.73 Global DBS Devices Market for Essential Tremor, 2018-2030 (Units, Volume)
Figure 14.74 DBS Devices Market for Essential Tremor in the US, 2018-2030 (Units, Volume)
Figure 14.75 DBS Devices Market for Essential Tremor in Canada, 2018-2030 (Units, Volume)
Figure 14.76 DBS Devices Market for Essential Tremor in the UK, 2018-2030 (Units, Volume)
Figure 14.77 DBS Devices Market for Essential Tremor in Germany, 2018-2030 (Units, Volume)
Figure 14.78 DBS Devices Market for Essential Tremor in France, 2018-2030 (Units, Volume)
Figure 14.79 DBS Devices Market for Essential Tremor in Spain, 2018-2030 (Units, Volume)
Figure 14.80 DBS Devices Market for Essential Tremor in Italy, 2018-2030 (Units, Volume)
Figure 14.81 DBS Devices Market for Essential Tremor in Australia, 2018-2030 (Units, Volume)
Figure 14.82 DBS Devices Market for Essential Tremor in China, 2018-2030 (Units, Volume)
Figure 14.83 DBS Devices Market for Essential Tremor in Japan, 2018-2030 (Units, Volume)
Figure 14.84 Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (Units, Volume)
Figure 14.85 DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (Units, Volume)
Figure 14.86 DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (Units, Volume)
Figure 14.87 DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (Units, Volume)
Figure 14.88 DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (Units, Volume)
Figure 14.89 DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (Units, Volume)
Figure 14.90 DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (Units, Volume)
Figure 14.91 DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (Units, Volume)
Figure 14.92 DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (Units, Volume)
Figure 14.93 DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (Units, Volume)
Figure 14.94 DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (Units, Volume)
Figure 14.95 Global DBS Devices Market for Dystonia, 2018-2030 (Units, Volume)
Figure 14.96 DBS Devices Market for Dystonia in the US, 2018-2030 (Units, Volume)
Figure 14.97 DBS Devices Market for Dystonia in Canada, 2018-2030 (Units, Volume)
Figure 14.98 DBS Devices Market for Dystonia in the UK, 2018-2030 (Units, Volume)
Figure 14.99 DBS Devices Market for Dystonia in Germany, 2018-2030 (Units, Volume)
Figure 14.100 DBS Devices Market for Dystonia in France, 2018-2030 (Units, Volume)
Figure 14.101 DBS Devices Market for Dystonia in Spain, 2018-2030 (Units, Volume)
Figure 14.102 DBS Devices Market for Dystonia in Italy, 2018-2030 (Units, Volume)
Figure 14.103 DBS Devices Market for Dystonia in Australia, 2018-2030 (Units, Volume)
Figure 14.104 DBS Devices Market for Dystonia in China, 2018-2030 (Units, Volume)
Figure 14.105 DBS Devices Market for Dystonia in Japan, 2018-2030 (Units, Volume)
Figure 14.106 Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (Units, Volume)
Figure 14.107 DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (Units, Volume)
Figure 14.108 DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (Units, Volume)
Figure 14.109 DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (Units, Volume)
Figure 14.110 DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (Units, Volume)
Figure 14.111 DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (Units, Volume)
Figure 14.112 DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (Units, Volume)
Figure 14.113 DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (Units, Volume)
Figure 14.114 DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (Units, Volume)
Figure 14.115 DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (Units, Volume)
Figure 14.116 DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (Units, Volume)
Figure 14.117 Global VNS Devices Market, 2018-2030 (USD Million)
Figure 14.118 Global VNS Devices Market for Epilepsy, 2018-2030 (USD Million)
Figure 14.119 VNS Devices Market for Epilepsy in the US, 2018-2030 (USD Million)
Figure 14.120 VNS Devices Market for Epilepsy in Canada, 2018-2030 (USD Million)
Figure 14.121 VNS Devices Market for Epilepsy in the UK, 2018-2030 (USD Million)
Figure 14.122 VNS Devices Market for Epilepsy in Germany, 2018-2030 (USD Million)
Figure 14.123 VNS Devices Market for Epilepsy in France, 2018-2030 (USD Million)
Figure 14.124 VNS Devices Market for Epilepsy in Spain, 2018-2030 (USD Million)
Figure 14.125 VNS Devices Market for Epilepsy in Italy, 2018-2030 (USD Million)
Figure 14.126 VNS Devices Market for Epilepsy in Australia, 2018-2030 (USD Million)
Figure 14.127 VNS Devices Market for Epilepsy in China, 2018-2030 (USD Million)
Figure 14.128 VNS Devices Market for Epilepsy in Japan, 2018-2030 (USD Million)
Figure 14.129 Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (USD Million)
Figure 14.130 VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (USD Million)
Figure 14.131 VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (USD Million)
Figure 14.132 VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (USD Million)
Figure 14.133 VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (USD Million)
Figure 14.134 VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (USD Million)
Figure 14.135 VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (USD Million)
Figure 14.136 VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (USD Million)
Figure 14.137 VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (USD Million)
Figure 14.138 VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (USD Million)
Figure 14.139 VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (USD Million)
Figure 14.140 Global VNS Devices Market, 2018-2030 (Units, Volume)
Figure 14.141 Global VNS Devices Market for Epilepsy, 2018-2030 (Units, Volume)
Figure 14.142 VNS Devices Market for Epilepsy in the US, 2018-2030 (Units, Volume)
Figure 14.143 VNS Devices Market for Epilepsy in Canada, 2018-2030 (Units, Volume)
Figure 14.144 VNS Devices Market for Epilepsy in the UK, 2018-2030 (Units, Volume)
Figure 14.145 VNS Devices Market for Epilepsy in Germany, 2018-2030 (Units, Volume)
Figure 14.146 VNS Devices Market for Epilepsy in France, 2018-2030 (Units, Volume)
Figure 14.147 VNS Devices Market for Epilepsy in Spain, 2018-2030 (Units, Volume)
Figure 14.148 VNS Devices Market for Epilepsy in Italy, 2018-2030 (Units, Volume)
Figure 14.149 VNS Devices Market for Epilepsy in Australia, 2018-2030 (Units, Volume)
Figure 14.150 VNS Devices Market for Epilepsy in China, 2018-2030 (Units, Volume)
Figure 14.151 VNS Devices Market for Epilepsy in Japan, 2018-2030 (Units, Volume)
Figure 14.152 Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (Units, Volume)
Figure 14.153 VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (Units, Volume)
Figure 14.154 VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (Units, Volume)
Figure 14.155 VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (Units, Volume)
Figure 14.156 VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (Units, Volume)
Figure 14.157 VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (Units, Volume)
Figure 14.158 VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (Units, Volume)
Figure 14.159 VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (Units, Volume)
Figure 14.160 VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (Units, Volume)
Figure 14.161 VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (Units, Volume)
Figure 14.162 VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (Units, Volume)
Figure 14.163 Global Other Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.164 Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (USD Million)
Figure 14.165 Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (USD Million)
Figure 14.166 Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (USD Million)
Figure 14.167 Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (USD Million)
Figure 14.168 Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (USD Million)
Figure 14.169 Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (USD Million)
Figure 14.170 Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (USD Million)
Figure 14.171 Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (USD Million)
Figure 14.172 Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (USD Million)
Figure 14.173 Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (USD Million)
Figure 14.174 Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (USD Million)
Figure 14.175 Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (USD Million)
Figure 14.176 Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (USD Million)
Figure 14.177 Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (USD Million)
Figure 14.178 Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (USD Million)
Figure 14.179 Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (USD Million)
Figure 14.180 Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (USD Million)
Figure 14.181 Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (USD Million)
Figure 14.182 Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (USD Million)
Figure 14.183 Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (USD Million)
Figure 14.184 Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (USD Million)
Figure 14.185 Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (USD Million)
Figure 14.186 Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (USD Million)
Figure 14.187 Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (USD Million)
Figure 14.188 Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (USD Million)
Figure 14.189 Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (USD Million)
Figure 14.190 Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (USD Million)
Figure 14.191 Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (USD Million)
Figure 14.192 Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (USD Million)
Figure 14.193 Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (USD Million)
Figure 14.194 Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (USD Million)
Figure 14.195 Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (USD Million)
Figure 14.196 Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (USD Million)
Figure 14.197 Global Other Neurostimulation Devices Market, 2018-2030 (Units, Volume)
Figure 14.198 Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (Units, Volume)
Figure 14.199 Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (Units, Volume)
Figure 14.200 Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (Units, Volume)
Figure 14.201 Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (Units, Volume)
Figure 14.202 Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (Units, Volume)
Figure 14.203 Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (Units, Volume)
Figure 14.204 Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (Units, Volume)
Figure 14.205 Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (Units, Volume)
Figure 14.206 Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (Units, Volume)
Figure 14.207 Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (Units, Volume)
Figure 14.208 Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (Units, Volume)
Figure 14.209 Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (Units, Volume)
Figure 14.210 Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (Units, Volume)
Figure 14.211 Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (Units, Volume)
Figure 14.212 Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (Units, Volume)
Figure 14.213 Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (Units, Volume)
Figure 14.214 Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (Units, Volume)
Figure 14.215 Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (Units, Volume)
Figure 14.216 Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (Units, Volume)
Figure 14.217 Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (Units, Volume)
Figure 14.218 Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (Units, Volume)
Figure 14.219 Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (Units, Volume)
Figure 14.220 Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (Units, Volume)
Figure 14.221 Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (Units, Volume)
Figure 14.222 Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (Units, Volume)
Figure 14.223 Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (Units, Volume)
Figure 14.224 Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (Units, Volume)
Figure 14.225 Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (Units, Volume)
Figure 14.226 Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (Units, Volume)
Figure 14.227 Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (Units, Volume)
Figure 14.228 Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (Units, Volume)
Figure 14.229 Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (Units, Volume)
Figure 14.230 Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (Units, Volume)
Figure 14.231 Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.232 Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (Units, Volume)
Figure 14.233 Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.234 Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (Units, Volume)

List of Tables

Executive Summary

Research Methodology
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view of the likely evolution of the neurostimulation devices market in the mid to long term.

Chapter 3 is an introductory chapter that presents a general overview of the epidemiology and the growing prevalence of chronic clinical conditions, along with information on the limitations of conventional treatment methods. Further, it features a detailed discussion on neurostimulation devices, including a comprehensive history of development, information on their basic components and principle of operation, and associated advantages/challenges. It also features a discussion on the key types of neurostimulation devices, including SCS, DBS, SNS, VNS, Other CNS, and other device types, featuring information on the potential applicability of these devices across different disease indications. Further, the chapter features a discussion on the key growth drivers and roadblocks related to neurostimulation and its use in treating various neurological conditions.

Chapter 4 provides a detailed description on the regulatory landscape related to medical devices across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan). Further, it provides information on the payer mix and details of the reimbursement processes of various public/private organizations across different geographies.

Chapter 5 includes information on more than 125 invasive neurostimulation devices that are either commercialized or under development for the treatment of different disorders. It features detailed analyses of these devices based on key specifications (including size, weight, battery type, battery longevity, number of electrodes, and MRI compatibility), Further, we have provided information on different types of neurostimulation devices, target nerves, target therapeutic areas, and regulatory approvals received across various geographies. The chapter also highlights the contributions of various companies engaged in this domain, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 6 provides a detailed review of SCS devices, along with information on their historical evolution and associated surgical procedures (for implantation). The chapter also presents a comprehensive 2 X 2 matrix to compare device competitiveness, by taking into consideration the supplier power (based on size of employee base) and certain device-related parameters, such as number of target indications, target nerves, regulatory approvals, and key specifications of the devices (including size, weight, battery type, battery longevity, number of electrodes, type of programming, and MRI compatibility). In addition, the chapter includes elaborate profiles of the developers of leading SCS devices (shortlisted on the basis of device competitiveness analysis scores); each profile features an overview of the company, its financial information (if available), detailed description of the device(s) and the recent developments and future outlook with respect to the specific device(s) / overall neurostimulation domain.

Chapter 7 provides a detailed review of DBS devices, along with information on their historical evolution and associated surgical procedures (for implantation). The chapter also presents a comprehensive 2 X 2 matrix to compare device competitiveness, by taking into consideration the supplier power (based on the size of the employee base) and certain device-related parameters. In addition, the chapter includes elaborate profiles of the developers of leading DBS devices (shortlisted on the basis of device competitiveness analysis scores); each profile features an overview of the company, its financial information (if available), detailed description of the device(s) and the recent developments and future outlook with respect to the specific device(s) / overall neurostimulation domain.

Chapter 8 provides a detailed review of PNS devices (including SNS, VNS and Other CNS devices), along with information on their historical evolution and associated surgical procedures (for implantation). The chapter also presents three comprehensive 2 X 2 matrices to compare device competitiveness within each type of PNS devices, by taking into consideration the supplier power (based on the size of employee base) and certain device-related parameters. In addition, the chapter includes elaborate profiles of the developers of leading devices within each type (shortlisted on the basis of respective device competitiveness analysis scores); each profile features an overview of the company, its financial information (if available), detailed description of the device(s) and the recent developments and future outlook with respect to the specific device(s) / overall neurostimulation domain.

Chapter 9 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of the strength of product portfolio) highlighting the current perceptions regarding their proprietary brands across different device types. The analysis takes into consideration several aspects, such as strength/diversity of product portfolio, strength of patent portfolio, recent collaborations, number of target indications and regulatory approvals, and the overall market positioning of the companies.

Chapter 10 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For the purpose of this analysis, we considered those patents that have been published since 2013 related to the neurostimulation domain. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, IP litigations, emerging areas, leading industry players, and patent benchmarking and valuation.

Chapter 11 provides a comprehensive clinical trial analysis of completed, ongoing and planned studies of various neurostimulation devices. For the purpose of this analysis, we looked at the clinical studies that have been last updated in 2013, and analyzed them on the basis of various parameters, such as current trial status, regional distribution, leading industry and non-industry players, key indications, and enrolled patient population across different geographies.

Chapter 12 features an elaborate discussion and analysis of the various partnerships/collaborations that have been inked amongst players in this market. It includes a brief description on the various types of partnership models (such as product development/commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers/acquisitions, and others) that have been employed by stakeholders in this domain, and analysis on the trend of partnerships inked since 2015. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to neurostimulation devices. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 13 provides information on the funding instances and investments that have been made in the neurostimulation domain. The chapter includes details on various types of investments (such as seed financing, venture funding, debt financing and grants) received by companies between 2015 and mid-2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 14 features a comprehensive market forecast, highlighting the future potential of neurostimulation devices till 2030 based on multiple parameters, such as prices of devices, indication/region specific adoption trends, and competitive landscape. We have segmented the market on the basis of type of neurostimulation devices (SCS, DBS, VNS, and other types), indication (chronic pain, dystonia, epilepsy, essential tremor, heart failure, major depressive disorder, Parkinson’s disease, obsessive-compulsive disorder, overactive bladder, and sleep apnea), MRI compatibility (MRI compatible and MRI non-compatible), and the geographical distribution of the market (US, Canada, UK, Germany, France, Spain, Italy, Australia, China, and Japan). We have adopted a bottom-up approach, backed by robust data and credible inputs from primary research, to estimate the likely size of the market, both in terms of value (USD billion) and volume (number of devices).

Chapter 15 presents a discussion on the upcoming opportunities/trends in the field of neurostimulation devices that are likely to impact the future evolution of this market over the coming years. These include (but not limited to) development of devices against unexplored therapeutic areas, integration of novel and advanced features, launch in different geographies, increased utilization of real-world evidence-based insights, and implementation of cybersecurity measures in the devices.

Chapter 16 is a collection of executive insights of the discussions that were held key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Dave Rosa (President and Chief Executive Officer, NeuroOne Medical Technologies), Deborah Schmalz (Vice President, Regulatory Affairs, Clinical Research and Compliance, ReShape Lifesciences) and Diane Utzman-O’Neill (Vice President, Marketing, ReShape Lifesciences), Jan Pieter Heemels (Vice President, Commercial Operations, Mainstay Medical), Laura Tyler Perryman (Chief Executive Officer, Stimwave), Luca Ravagnan (Chief Executive Officer, WISE), and Steve Goedeke (President and Chief Executive Officer, Cardionomic)

Chapter 17 is an appendix, which provides a comprehensive list of non-invasive neurostimulation devices, along with information on their developers, types of non-invasive neurostimulation technologies, target therapeutic areas, and development/approval status of the devices.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Abbott
Aberdare Ventures
Academy Medical Center
Accelmed Growth Partners
Action Potential Venture Capital
AcuKnee
AdvaStim
Advent Life Sciences
Aetion
Aetna
AG2R La Mondiale
Alan Neuromedical Technologies
ALC Healthcare
Alere
Aleva Neurotherapeutics
Alfred Mann Foundation
Allergan
Allianz
American Academy of Neurology
American Academy of Pain Medicine
American Medical Association
Amzak Health
Andera Partners
Anomali
Antares Capital
Anthem
Aperture Venture Partners
ARAG Group
Atlante Ventures
Atrotech
Attivo Networks
Aucta Technologies
Autonomic Technologies
Autonomix Medical
Avery Biomedical Devices
Aviva
AXA PPP Healthcare
Axilum Robotics
Axiobionics
Axonic Capital
Axonics Modulation Technologies
b-to-v Partners
Banexi Ventures
Barclays
Bayer
BB Biotech Ventures
BC Platforms
Becton Dickinson
Beijing PINS Medical
Beijing Tiantan Hospital
Biegler
BioControl Medical
BioElectronics
Bioinduction
BioMedical Life Systems
BioMedPartners
Bioness
BioScience Managers
BioWave
BioWin
BlueWind Medical
Boston Scientific
Brain State Technologies
Brainlab
BrainsGate
BrainsWay
Bupa
Cala Health
Calmare Therapeutics
Canadian Agency for Drugs and Technologies in Health
Cancer Prevention and Research Institute of Texas
Capricorn Venture Partners
Carbon Black
Cardionomic
Carlos III Health Institute
Case Western Reserve University
Caser Seguros
Catholic University of Leuven
CBC Banque & Assurance
CEFALY Technology
Celgene
CensorNet
Center for Sensorimotor Neural Engineering
Centers for Medicare & Medicaid Services
Centripetal Networks
Centro of Construction of Cardiac Stimulators of Uruguay
Cerbomed
Cerevast Medical
Certara
Cervel Neurotech
Chattem
Cibiem
CICA
Cigna
Clearly Present Foundation
Cleveland Clinic
Clinakos
Clinigen Group
Cogentix Medical
Coridea
Cormorant Asset Management
Cosman Medical
Covidien
CrowdStrike
Crédit Mutuel Group
CVRx
Cylance
Darktrace
Deep Brain Innovations
Defense Advanced Research Projects Agency
Deutsche Krankenversicherung
DEYMED Diagnostic
Dolphin Neurostim
Dr. Langer Medical
DyAnsys
EaglePicher Medical Power
EBS Technologies
electroCore
ElectroMedical Technologies
Electronic Waveform Lab
Elron Electronic Industries
ELvation
Endeavour Vision
Endonovo Therapeutics
EndoStim
eNeura
Enopace Biomedical
Enspire DBS Therapy
Epimed International
ERGO Group
Evergreen Medical Technologies
Evidera
Exabeam
Expatriate Healthcare
F3F
Federal Holding and Investment Company
Finetech Medical
FireEye
Firstkind
Fisher Wallace Laboratories
Flashpoint
Flatiron Health
Flow Neuroscience
Fogarty Institute for Innovation
Forbion Capital Partners
Forrestal Capital
Fortinet
Fountain Healthcare Partners
Freedom Health
French National Authority for Health
Frontcourt Ventures
Functional Neuromodulation
FundRx
Gala Therapeutics
Galvani Bioelectronics
Generali Deutschland
German Institute of Medical Documentation and Information
Gigamon
Gilde Healthcare Partners
GiMer Medical
Gimv
GlaxoSmithKline
Gradient Medical
Greatbatch
Green Park & Golf Ventures
GTX Medical
Hannover Re
HBM Healthcare Investments
HealthCore
Helius Medical Technologies
Helpucover
HiDow
High-Tech Gründerfonds
Hollywog
Horowitz Group
Humana
Humanitas Clinical Institute
ICON
INC Research
InCube Labs
Indegene
IndependiCare
Ingress Health
Initiative Capital Romandie
INKEF Capital
Innogest Capital
Innovative Health Solutions
Inspire Medical Systems
Institute for Hospital Remuneration System
Institute for Industrial Science
Institute for Quality and Efficiency in Health Care
Institute of Hospitalization and Care of Scientific Character
Institute of Medical Arts
InterWest Partners
InterX Technologies
IntraPace
IPF Partners
IQVIA
iTENS
Johari Digital Healthcare
Johnson & Johnson
JumpStart
Kairuku
Kaiser Permanente
KCK Group
Kinled Holding
Kleiner Perkins
La Luxembourgeoise
LABORIE Medical Technologies
Legend Capital Management
Leonite Capital
Lightstone Ventures
Linguamatics
LivaNova
LogRhythm
Lone Star Neuromodulation
Longitude Capital
LSP
Lungpacer Medical
MAAF Assurances
MAG & More
Magstim
MagVenture
Mainstay Medical
Massachusetts Life Science Center
Mayo Clinic
Mayo Foundation for Medical Education and Research
McAfee
McKesson
MDC Partners
Meagan Medical
Med-Ally
Medaffcon
Medi-Line
Medical University of South Carolina
Medicines and Healthcare products Regulatory Agency
Medisana
MedSec
Medtronic
MEMStim
Mercy
Metavention
Micro-Leads
MicroTransponder
Minnetronix
Morgenthaler
Munich Re
MyndTec
National Agency for Medicines and Health Products Safety
National Engineering Laboratory for Neuromodulation
National Institute of Excellence in Health and Social Services
National Institute of Health and Clinical Excellence
National Institute of Medical Sciences and Nutrition Salvador Zubiran
National Institutes of Health
National Neuroscience Institute
Nature's Gate
NeoMed Management
NeoSync
Nervana Systems
Netherlands Enterprise Agency
Neuralieve
neuroCare
Neuroelectrics
NeuroEM Therapeutics
NeuroHabilitation
NeuroMetrix
Neuromod
Neuronetics
NeuroOne Medical Technologies
NeuroPace
NeuroQore
NeuroRecovery Technologies
Neuros Medical
NeuroSigma
NeuroTek Medical
Neurova
Neurowave Medical Technologies
Nevro
New Enterprise Associates
Newronika
Newton Biocapital
Nexeon MedSystems
Nexstim
Nia Therapeutics
Niveus Medical
Novallia
Novartis
NTLab
Nuvectra
Nyxoah
Ohio Third Frontier
OMRON Healthcare
OrbiMed Advisors
Oregon Health & Science University
Orthofix
Osage University Partners
Ottobock
Oxford Finance
Pain Alliance Europe
PainPod BioTechnology
Palantir
Palo Alto Networks
Parasym Health
PAREXEL
PathMaker Neurosystems
PerkinElmer
Pharmaceuticals and Medical Devices Agency
PhysIOL
Ping An Insurance
PlatoScience
Presidio Partners
Principia SGR
Prizm Medical
ProtectWise
Rainbow Medical
Reeve Foundation
Regional investment Company of Wallonia
RenalGuard Solutions
Renewal Technologies
ReShape Lifesciences
Respicardia
RITM
Ritmedic
Saama Technologies
Saga Health Insurance
Saluda Medical
Samsung Electronics America
Sanderling Ventures
Sanitas
Santé Ventures
Sapiens Steering Brain Stimulation
Scion NeuroStim
SegurCaixa Adeslas
Sensory NeuroStimulation
SetPoint Medical
Shape Security
SHYFT Analytics
Siemens
Silicon Valley Bank
Silk’n Therapy
Smiths Medical
Sofinnova Partners
Sophos
Soterix Medical
Southern California Permanente Medical Group
SPR Therapeutics
St. Jude Medical (Abbott)
StimGuard
StimRelieve
Stimwave
SUBLIMED
SUNMAS
Synapse Biomedical
Synergia Medical
Syntilla Medical
Tal Medical
Tempus
TENS Rx
Theranica Bio-Electronics
Threat Stack
Thync
Topspin Partners
TraceSecurity
Trustwave
Tsinghua University
TYRX
Ultra Care Systems
UnitedHealthcare
University of Brussels
University of California
University of Milan
University of Minnesota
University of New Mexico
University of Pittsburgh
University of Tokyo
University of Washington
US Department of Defense
US Department of Homeland Security
US Venture Partners
USCI Japan
VA Office of Research and Development
Valencia Technologies
Valtronic
Vectra Networks
Vention
Venture Bank
Versant Ventures
Virility Medical
Vision Sciences
Vital Motion
VitalityHealth
Wellington Partners
Windham Venture Partners
Wisconsin Alumni Research Foundation
WISE
Xavant Technology
Yongjin Group
Ysios Capital Partners
Zenedge
Zephyr Health
ZOLL Medical
ZTE
Zynex Medical

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3457EUR$3,499USD£2,878GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7904EUR$7,999USD£6,578GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€14820EUR$14,999USD£12,335GBP

Table of Contents

Executive Summary

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Neurostimulation Devices Market Report by Stimulation Type, Device Type, Application, End-User, and Region 2024-2032

Neurostimulation Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Neurostimulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

Neurostimulation Devices Global Market Report 2024

Neurostimulation Devices Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F